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Calreticulin is a pleiotropic molecule that normally resides in the lumen of the endoplas-
mic reticulum (ER). Here, it has various functions, ranging from regulation of calcium
homeostasis to ensuring proper protein folding. More recently, calreticulin gained spe-
cial interest for its extracellular functions, where it has direct immunomodulatory activity.
In this respect, calreticulin activates dendritic cells and macrophages. In addition, certain
anti-cancer therapies induce the translocation of calreticulin from the ER to the cell sur-
face of dying cancer cells, where calreticulin dictates the immunogenicity of these cells.
Interestingly, treatment with tumor necrosis factor (TNF)-related apoptosis inducing ligand
(TRAIL) also induces membrane calreticulin exposure on cancer cells. As shown here, cal-
reticulin directly interacts with TRAIL and its receptor-signaling complex, as well as with
other TNF family members. Of note, TRAIL is a well known immunomodulatory molecule,
and is expressed on the surface of natural killer T-cells. Therefore, calreticulin may have
an as yet unrecognized wide(r) impact on immunity, with theTNF-ligand family modulating
virtually all aspects of the immune response.
Keywords: calreticulin,TNF, tumor necrosis factor related apoptosis inducing ligand, immunomodulation, immuno-
genic cell death, complex formation
INTRODUCTION
The endoplasmic reticulum (ER)-resident protein calreticulin is
a pleiotropic molecule with many functions in the ER, rang-
ing from protein folding, calcium homeostasis, and regulation of
loading of antigenic peptides into major histocompatibility class
I (MHCI) (1, 2). Thus, ER-resident calreticulin has an important
impact on development and correct execution of immunity. How-
ever, in recent years, calreticulin has taken center stage not for its
ER-related functions, but for its newly uncovered immunomod-
ulatory effects in the extracellular space. It has become evident
that ER chaperones such as calreticulin function as danger associ-
ated molecular pattern molecules (DAMPs) once outside the cell
(3). For instance, when present on the cell surface of dendritic
cells (DCs) calreticulin functions as a receptor for autocrine-
produced complement factor 1q (C1q), which is upregulated
during CD40L/CD40 signaling, a key T helper signal required
for effective DC maturation (4). In addition, soluble calreticulin
promotes differentiation of CD1dhi CD5+ B-cells into antibody-
secreting cells (5). Further, soluble calreticulin induced TNF-α and
IL-6 release from macrophages, which was regulated by scavenger
receptor A (6).
A further prominent pro-immunogenic feature of extracel-
lular calreticulin is its key role in the process of immuno-
genic cell death (ICD) (7). ICD is a type of apoptosis that is
induced by certain chemotherapeutics or radiation, which pro-
motes phagocytic uptake of apoptotic cells by professional antigen
presenting cells, i.e., myeloid-derived DCs. Briefly, anthracycline
or radiation therapy trigger the translocation of calreticulin to
the pre-apoptotic tumor cell surface, which is dependent on the
induction of an ER-stress response (8, 9). Cell surface exposed
calreticulin then promotes clearance of the dying cancer cells by
DCs, with subsequent release of ATP, HMGB1, and HSP70 from
late apoptotic cells giving requisite cues for DC maturation and
clonal T-cell expansion (10).
Immunogenic cell death has been described in a preclinical set-
ting for an ever-expanding set of cytotoxic therapies, including
many chemotherapeutics, radiation therapy, and photodynamic
therapy. Interestingly, also treatment of cancer cells with a recom-
binant form of the tumor necrosis factor (TNF)-related apopto-
sis inducing ligand (TRAIL) was reported to induce calreticulin
exposure and ICD (11). TRAIL is a member of the TNF super-
family that can bind to a set of five receptors; TRAILR1 (DR4),
TRAILR2 (DR5), TRAIL-R3 (DcR1, TRID), TRAIL-R4 (DcR2,
TRUNDD), and soluble osteoprotegerin. Binding of TRAIL to
its agonistic receptors TRAILR1 and TRAILR2 induces assembly
of the so-called death inducing signaling complex (DISC) to the
intracellular death domain (DD). The DISC contains the adaptor
molecule Fas-associated protein with death domain (FADD) and
the pro-form of initiator caspase-8, which is auto-proteolytically
processed in the DISC. Activation of caspase-8 triggers a pro-
teolytic caspase cascade that ultimately leads to the execution
of apoptosis. Of note, the pro-apoptotic signaling of the DISC
can be inhibited by recruitment of additional regulators, such as
cFLIP (12).
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TNF-related apoptosis inducing ligand is an important
immune effector molecule that is expressed on various types of
immune cells including natural killer (NK) cells, T-cells, and nat-
ural killer T-cells (NKT cells) (13). Expression of TRAIL on T-cells
is further increased during T-cell receptor (TCR) stimulation
in the presence of interferon-γ (IFNγ) (14). Similarly, IFNγ-
mediated activation of NK-cells, monocytes, and DCs enhances
the expression of TRAIL on these cells (15, 16). TRAIL and its
receptors (TRAILRs) play an important role in anti-tumor immu-
nity, e.g., being involved in the immune surveillance for (metasta-
tic) cancer cells by liver NK-cells (17). Thus, the induction of
calreticulin exposure upon treatment with recombinant TRAIL
may be related to a possible immunoregulatory effect of TRAIL
in the context of its normal role on immune effector cells. Inter-
estingly, calreticulin can also interact directly with TRAIL in a
catching-type ELISA, as well as with the immunoregulatory TNF
family members such as CD40 ligand (CD40L) and FasL (18). In
contrast, calreticulin did not interact with TNF-α, adiponectin,
or CD30L. The reported activation of ICD upon treatment with
recombinant TRAIL suggests that calreticulin may regulate the
pro-immunogenic effect of TRAIL during anti-tumor immunity.
CALRETICULIN DIRECTLY INTERACTS WITH PRO-APOPTOTIC
TNF-LIGANDS AND RECEPTOR COMPLEXES
Calreticulin was recently reported to bind to TNF family member
FasL in the synovial fluid of rheumatoid arthritis (RA) patients.
This FasL/calreticulin interaction inhibited FasL-induced apop-
tosis of Jurkat T-cells (19). Since patients with RA have elevated
levels of calreticulin in their serum, this might inhibit apoptosis of
inflammatory T-cells in this particular disease. Our own studies
confirm a similar direct interaction of calreticulin with TRAIL,
as evidenced by, e.g., fluorescent microscopy for calreticulin and
TRAIL on the cell surface of TRAIL-treated A375M melanoma
cells and not in control cells (Figure 1A). This is in line with
the reported translocation of calreticulin to the cell surface of
apoptotic HeLa cells by recombinant TRAIL (11). Interestingly,
calreticulin also strongly co-localized with TRAILR2 on TRAIL-
treated A375M cells (Figures 1B,C), with calreticulin, TRAIL, and
TRAILR2 all being in one complex co-precipitated upon anti-HA-
TRAIL immunoprecipitation experiments (Figure 1D). Similarly,
calreticulin was immunoprecipitated in the FasL/Fas DISC (data
not shown). The association of calreticulin with TRAILR2 occurs
in a clear patched pattern on the cell surface (Figures 1B,C), a
pattern corresponding to that of the patched foci to which calreti-
culin redistributed on the cell membrane of apoptotic neutrophils
(20), on mitoxantrone treated CT26 colon cancer cells (21), and
hypericin-treated bladder cancer cells (22).
The recruitment of calreticulin in distinct patches on the cell
membrane has been shown to facilitate engulfment of apop-
totic cells by phagocytes induced by UV radiation or anthracy-
cline therapy (7, 20) (Figure 2A). These calreticulin-rich patches
also contained high levels of phosphatidylserine (PS), an apop-
totic marker that provides strong “eat me” signals for phagocytes
(20). Correspondingly, calreticulin binds in a Ca2+-dependent
manner directly to the polar head of PS with high affinity
(KD= 1.5× 10−5 M) (24). This recruitment of calreticulin into
lipid rafts was dependent on ERp57 (21,25). Of note,on the surface
of viable cells calreticulin is associated with CD47, a prominent
so-called “don’t eat me” signal that blocks phagocytosis by bind-
ing to the inhibitory receptor SIRPα on phagocytes (26). During
apoptosis, calreticulin dissociates from CD47 and associates with
PS; a shift that promotes phagocytosis (20). Of note, the balance
between pro-phagocytic calreticulin and anti-phagocytic CD47
has also been described in multiple human cancer cells, with can-
cer cells often being characterized by CD47 overexpression to elude
phagocytic removal (26, 27). Similarly, our experiments indicate
that calreticulin dissociates from CD47 upon TRAIL treatment of
A375M cells (Figure 1C). Together with literature, this dissocia-
tion suggests that the interaction of calreticulin with TRAIL and
TRAILR2 may facilitate phagocytic clearance (Figure 2B).
CALRETICULIN IS RECRUITED TO ACTIVE SIGNALING
COMPLEXES OF THE TNFR SUPERFAMILY
In an earlier study on TNFR-signaling, surface expressed calretic-
ulin was reported to be recruited to TNF receptor 1 (TNFR1) and
its adaptor TNFR-associated death domain (TRADD) upon treat-
ment with bacterial peptidoglycan N -acetylmuramyl-l-alanyl-d-
isoglutamine (l,d-MDP) (28). This interaction was independent
of TNF and triggered apoptosis in RK13 kidney cells that could
be blocked by anti-calreticulin antibodies. Similarly, calreticulin
associated with TRAIL, TRAILR2, as well as adaptor protein FADD
and pro-caspase-8 in A375M melanoma cells (Figures 1D,E). Of
note, caspase-8 was predominantly present in its pro-form after
15 min of TRAIL treatment, but was in its processed p41/43 form
after 180 min. Further, caspase-8 processing occurred mainly at
37°C, although treatment on ice also induced DISC formation
(Figures 1D,E). The interaction of calreticulin with TRAIL was
necessary for its association with TRAILR2 as calreticulin was not
co-immunoprecipitated with TRAILR2 upon treatment with ago-
nistic TRAILR2 antibody, despite DISC formation (Figure 1F).
Thus, physical interaction of TRAIL with calreticulin mediates its
recruitment to the TRAILR2 DISC.
CALRETICULIN ASSOCIATION WITH THE TRAILR2–DISC
DEPENDS ON RAFT REORGANIZATION BUT IS
INDEPENDENT OF APOPTOTIC SIGNALING
During ICD with mitoxantrone, the maximum level of surface
exposed calreticulin was observed within 15 min, and remained at
stable levels for at least 24 h (7). In line with this, surface calretic-
ulin became visible after 30 min on neutrophils and continued to
increase as neutrophils became more apoptotic (20). In contrast,
induction of ICD upon treatment of Hela cells with TRAIL only
induced detectable levels of calreticulin on the surface after 24 h of
incubation (11). On A375M cells, calreticulin translocated to and
associated with calreticulin with TRAIL already after 15 min, with
maximal association after 1 h (Figure 1G), which corresponded to
the maximum level of processed caspase-8 (p43/41) (Figure 1H).
Further, the maximum association of calreticulin with TRAIL and
the DISC occurs before the execution of apoptosis, as determined
by activation of effector caspases-3 and -7 (Figure 1H). This
dynamic corresponds to the pre-apoptotic exposure of calreticulin
during ICD (7). Interestingly, induction of apoptosis was required
to induce cell surface calreticulin exposure upon treatment with
mitoxantrone, with depletion of caspase-8 completely abolishing
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FIGURE 1 | Calreticulin binds toTRAIL and associates with the
TRAILR2–DISC. (A) A375M cells were treated with 100 ng/ml rhTRAIL for
1 h, incubated with mAbs directed against calreticulin (Ab2907, Abcam) and
TRAIL (B-S23, Diaclone), or isotype controls, and subsequently analyzed by
proximity ligation assay (Duolink II, Olink Biosciensce) (distance between
both proteins; <40 nM or ~4–12 proteins). (B) A375M cells were treated with
100 ng/ml rhTRAIL for 1 h, double stained for calreticulin (red; Ab2907,
Abcam) and TRAILR2 (green; HS-201, Alexis) and analyzed using confocal
fluorescent microscopy. (C) As in (A), but the proximity ligation assay were
performed using mAbs directed against calreticulin (Ab2907, Abcam),
TRAILR2 (HS-201, Alexis), and CD47 (ab3283, Abcam). (D) A375M cells were
treated with HA-TRAIL [constructed by cloning the cDNA of HA-tagged TRAIL
in frame into previously described vector pEE14 (23), yielding
pEE14-HA-TRAIL] for 15 or 180 min at the indicated temperatures. Cells were
subsequently lysed and HA-TRAIL was precipitated via affinity tag purification
(HA-sepharose beads; 3F10, Roche). Precipitates were subsequently probed
for the presence of HA (3F10, Roche), calreticulin (Ab39818, Abcam),
TRAILR2 (HS-201, Alexis), FADD (272S, cell signaling), and caspase-8 (18C8,
cell signaling). (E) As in (D), but precipitated using anti-calreticulin.
Precipitates were subsequently probed for the presence of calreticulin, HA,
and caspase-8. (F) A375M melanoma cells were treated with HA-TRAIL or
agonistic TRAILR2 mAb for 60 min at 37°C. Cells were subsequently lysed
and TRAILR2 was precipitated. The precipitates were probed for the presence
of HA, calreticulin, TRAILR2, and caspase-8. (G) A375M cells were treated
with HA-TRAIL at 37°C for the indicated time-points. Cells were subsequently
lysed and HA-TRAIL (upper panel) or calreticulin (lower panel) were
precipitated. Precipitates were subsequently probed for the presence of
calreticulin or HA-TRAIL, respectively. (H) A375M cells were treated with
HA-TRAIL at 37°C for the indicated time-points.  Quantification of
caspase-8 (p42/41) association with TRAIL as determined by
immunoprecipitation caspase-3/-7 activity as determined by flow cytometry
(CellEvent caspase-3/-7 probe, Invitrogen). (I) Ramos, Ramos.cFLIPL,
Ramos.cFLIPS, and Ramos.Ezrin cells were treated with HA-TRAIL for 1 h at
37°C. Cells were subsequently lysed and HA-TRAIL was precipitated via
affinity tag purification. Precipitates were subsequently probed for the
presence of calreticulin. (J) Ramos, Ramos.cFLIPL, Ramos.cFLIPS, and
Ramos.Ezrin cells were treated with rhTRAIL for 16 h and apoptosis was
assessed (DioC6 staining, flow cytometry using BD Accuri Flow cytometer).
***p<0.001. (K) A375M cells were treated with HA-TRAIL in the presence
or absence of 20µM zVAD-fmk (CalBiochem). Subsequently, calreticulin was
precipitated and the precipitates were stained for HA-TRAIL. Association of
calreticulin and TRAIL is depicted as percentage of maximum association.
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FIGURE 2 | Immunomodulatory role of calreticulin in cancer
immunity (A). In (tumor) cells, calreticulin predominantly resides in the
ER. Upon induction of immunogenic cell death (ICD) by, for instance,
anthracycline or radiation therapy, calreticulin translocates to the surface
of pre-apoptotic cells. In addition, surface exposed calreticulin (eat me
signal) dissociates from CD47 (don’t eat me signal), whereupon the
apoptotic cancer cells can be recognized and taken up by DCs. (B)The
binding of TRAIL to its receptor (TRAILR2) results in the translocation of
calreticulin to the cell surface of cancer cells, whereby a complex is
formed between TRAIL, TRAILR2–DISC, and calreticulin. Simultaneously,
calreticulin dissociates from CD47. The formation of the TRAIL/TRAILR2/
Calreticulin-complex may have different outcomes: (1) As described for
the concept of ICD, cell surface exposure of calreticulin and dissociation
from CD47 induced by TRAIL treatment may facilitate phagocytic uptake
by DCs. (2) the binding of calreticulin to TRAIL and TRAILR2 may impair
phagocytic clearance by DCs, as calreticulin may be segregated away
from the membrane microdomains in which it can partake in the
phagocytic uptake by DCs.
the translocation of calreticulin (11). In contrast, inhibition of
caspase-8 did not inhibit calreticulin exposure upon photody-
namic therapy with hypericin (9). In line with the latter report,
calreticulin was still co-precipitated with TRAIL in Ramos B-cells
that are resistant to TRAIL-mediated apoptosis by overexpres-
sion of the anti-apoptotic DISC component cFLIP (Ramos.cFLIPL
and Ramos.cFLIPs) (Figures 1I,J). Correspondingly, co-treatment
of A375M cells with TRAIL and pan-caspase-inhibitor zVAD-
fmk did not abrogate the association of calreticulin with TRAIL
(Figure 1K).
During ICD, the actin cytoskeleton was required for transloca-
tion of calreticulin to the pre-apoptotic cell surface (11). Similarly,
calreticulin–TRAIL association was dependent on cytoskeletal
rearrangements and was abolished in Ramos cell overexpressing
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the double negative Ezrin mutant (DN-Ezrin), which is incapable
of interacting with actin (Figure 1I). Thus, calreticulin associa-
tion with the DISC is independent of apoptosis, but dependent on
cytoskeletal reorganization.
CONCLUSION/FUTURE DIRECTIONS
It is clear from literature that treatment of cancer cells with TRAIL
can induce calreticulin relocalization to the cell surface. Further,
as evidenced by the data in the current manuscript, surface cal-
reticulin is recruited to the TRAIL/TRAILR/DISC complex and
dissociates from CD47. Together, these observations suggest that
calreticulin could promote phagocytosis of apoptotic cells upon
TRAIL-mediated killing (Figure 2B). On the other hand, its asso-
ciation with the TRAILR2–DISC might render calreticulin unable
to effectuate pro-immunogenic removal of target cells by DCs.
In this respect, it is tempting to speculate that by binding to the
TRAILR2–DISC, calreticulin is segregated away from the mem-
brane microdomains in which it can partake in the phagocytic
uptake of target cells by DCs or other phagocytes (Figure 2B).
These findings would be consistent with the non-immunogenic
clearance of cells undergoing TRAIL-mediated programed cell
death (29). To gain insight in the possible immunomodulatory
role of calreticulin during TRAIL-induced apoptosis, it will be
imperative to characterize the particular complex or membrane
microdomain in which calreticulin resides in the context of ICD.
Comparison of calreticulin localization upon treatment with typ-
ical immunogenic inducers, and how this compares to its local-
ization during TRAIL-mediated cell death may shed light on its
particular role.
The inhibition of FasL-mediated T-cell death by calreticulin,
the direct induction of apoptosis by l,d-MDP-bound calretic-
ulin via TNFR1 and the here described association of calreticulin
to TRAILR2 during TRAIL-mediated cell death suggest a much
broader role for calreticulin in the antitumor immune response
than as a mediator of ICD. By directly modulating apoptosis and
associating with key apoptotic players, calreticulin could function
as a bridge between innate and adaptive immunity. In this par-
adigm, induction of programed cell death by immune effector
molecules, such as TRAIL and FasL, induces a rapid pre-apoptotic
translocation of calreticulin to the cell surface. On the cell sur-
face, calreticulin can then either modulate induction of cell death
as described for FasL (19) or translocate to specific cell surface
microdomains (with or without receptors of the TNF super-
family), thereby modulating phagocytosis and pro-immunogenic
DC-mediated removal. In its soluble state, secretion of calreticulin
in response to apoptotic stimuli can directly affect the immediate
early innate immune response by modulating cytokine secre-
tion of macrophages. Interestingly, agonistic TRAIL-receptors
have been reported as negative regulators of innate immune
responses (30). An intriguing possibility currently being inves-
tigated in our laboratory is that sequestration of calreticulin by
TRAIL-receptors could contribute to limiting activation of innate
immunity.
Calreticulin exposure can further trigger activation of the adap-
tive immune response by promoting immunogenic DC-uptake of
apoptotic cells during ICD. In this respect, it is also of interest
that of all the TNF ligands it was found to interact with in a
catching-type ELISA, calreticulin most strongly associated with
CD40L. Thus, recruitment of calreticulin to CD40L/CD40 sig-
naling complexes may impact DC activity. Whether calreticulin
directly associates with TNF family members beyond CD40, FasL,
and TRAIL has not been identified, to date. However, the reported
interaction of calreticulin with several TNF-ligand family mem-
bers points to the possibility that calreticulin may have an as yet
unrecognized wide(r) impact on immunity, with the TNF ligand
family modulating virtually all aspects of the immune response.
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